Brokerages Set Kalaris Therapeutics Inc. (NASDAQ:KLRS) Target Price at $18.75

Shares of Kalaris Therapeutics Inc. (NASDAQ:KLRS) have been assigned an average rating of “Moderate Buy” from the seven research firms that are currently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating and six have issued a buy rating on the company. The average twelve-month target price among brokers that have covered the stock in the last year is $18.75.

A number of analysts recently commented on KLRS shares. Wall Street Zen upgraded shares of Kalaris Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday. Weiss Ratings cut shares of Kalaris Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, July 28th. Wedbush assumed coverage on shares of Kalaris Therapeutics in a research report on Thursday, May 14th. They issued an “outperform” rating and a $17.00 price target on the stock. Citizens Jmp dropped their price target on Kalaris Therapeutics from $26.00 to $25.00 and set a “market outperform” rating on the stock in a report on Wednesday, May 13th. Finally, TD Cowen initiated coverage on Kalaris Therapeutics in a research report on Monday, June 15th. They set a “buy” rating for the company.

Hedge Funds Weigh In On Kalaris Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. State Street Corp raised its holdings in Kalaris Therapeutics by 12.4% during the 4th quarter. State Street Corp now owns 25,410 shares of the company’s stock worth $214,000 after buying an additional 2,800 shares during the period. Nano Cap New Millennium Growth Fund L P acquired a new position in shares of Kalaris Therapeutics in the fourth quarter worth about $34,000. Barclays PLC acquired a new position in shares of Kalaris Therapeutics in the fourth quarter worth about $51,000. Velan Capital Investment Management LP increased its position in shares of Kalaris Therapeutics by 38.9% in the second quarter. Velan Capital Investment Management LP now owns 25,000 shares of the company’s stock worth $102,000 after acquiring an additional 7,000 shares in the last quarter. Finally, Johnson Financial Group Inc. purchased a new position in shares of Kalaris Therapeutics in the third quarter worth approximately $58,000. Institutional investors and hedge funds own 66.05% of the company’s stock.

Kalaris Therapeutics Price Performance

Shares of KLRS stock opened at $3.90 on Monday. The stock has a 50-day simple moving average of $4.13 and a 200 day simple moving average of $5.58. Kalaris Therapeutics has a fifty-two week low of $3.03 and a fifty-two week high of $11.88. The stock has a market capitalization of $92.86 million, a P/E ratio of -1.93 and a beta of 0.22.

Kalaris Therapeutics (NASDAQ:KLRS) last issued its quarterly earnings results on Tuesday, August 11th. The company reported ($0.48) EPS for the quarter, topping the consensus estimate of ($0.50) by $0.02. On average, sell-side analysts anticipate that Kalaris Therapeutics will post -1.99 earnings per share for the current year.

Kalaris Therapeutics Company Profile

Allovir, Inc, a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company’s lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108.